Anika Therapeutics, Inc. (ANIK)
20.87
-0.23
(-1.09%)
USD |
NASDAQ |
Aug 31, 16:00
20.64
-0.23
(-1.10%)
After-Hours: 20:00
Anika Therapeutics Total Long Term Debt (Quarterly) : 23.32M for June 30, 2026
Total Long Term Debt (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Long Term Debt (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 23.32M |
| March 31, 2026 | 23.79M |
| December 31, 2025 | 24.20M |
| September 30, 2025 | 22.78M |
| June 30, 2025 | 23.17M |
| March 31, 2025 | 23.56M |
| December 31, 2024 | 24.01M |
| September 30, 2024 | 25.24M |
| June 30, 2024 | 25.79M |
| March 31, 2024 | 26.34M |
| December 31, 2023 | 25.92M |
| September 30, 2023 | 27.25M |
| June 30, 2023 | 27.78M |
| March 31, 2023 | 28.28M |
| December 31, 2022 | 28.82M |
| September 30, 2022 | 29.18M |
| June 30, 2022 | 29.86M |
| March 31, 2022 | 18.94M |
| December 31, 2021 | 19.43M |
| September 30, 2021 | 19.64M |
| June 30, 2021 | 20.08M |
| March 31, 2021 | 20.66M |
| December 31, 2020 | 21.03M |
| September 30, 2020 | 46.30M |
| June 30, 2020 | 71.60M |
| Date | Value |
|---|---|
| March 31, 2020 | 21.94M |
| December 31, 2019 | 21.37M |
| September 30, 2019 | 21.60M |
| June 30, 2019 | 21.97M |
| March 31, 2019 | 22.23M |
| December 31, 2018 | 0.00 |
| September 30, 2018 | 0.00 |
| June 30, 2018 | 0.00 |
| March 31, 2018 | 0.00 |
| December 31, 2017 | 0.00 |
| September 30, 2017 | 0.00 |
| June 30, 2017 | 0.00 |
| March 31, 2017 | 0.00 |
| December 31, 2016 | 0.00 |
| September 30, 2016 | 0.00 |
| June 30, 2016 | 0.00 |
| March 31, 2016 | 0.00 |
| December 31, 2015 | 0.00 |
| September 30, 2015 | 0.00 |
| June 30, 2015 | 0.00 |
| March 31, 2015 | 0.00 |
| December 31, 2014 | 0.00 |
| September 30, 2014 | 0.00 |
| June 30, 2014 | 0.00 |
| March 31, 2014 | 0.00 |
Total Long Term Debt Definition
Represents a company's total debt maturing for more than 12 months of the reporting period.
Total Long Term Debt (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Long Term Debt (Quarterly) Benchmarks
| Perspective Therapeutics, Inc. | 2.866M |
| MiMedx Group, Inc. | 17.21M |
| ABVC BioPharma, Inc. | 1.406M |
| Enovis Corp. | 1.344B |
| Edwards Lifesciences Corp. | 680.30M |